Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study

Digestive and Liver Disease

Volumn 46, Issue 2, 2014, Pages 135-139

  Cesarini, Monica ^a   Katsanos, Konstantinos ^b   Papamichael, Konstantinos ^c   Ellul, Pierre ^d   Lakatos, Peter L ^e   Caprioli, Flavio ^f,g   Kopylov, Uri ^h   Tsianos, Epameinondas ^b   Mantzaris, Gerassimos J ^c   Ben Horin, Shomron ^h   Danese, Silvio ⁱ   Fiorino, Gionata ⁱ  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d MATER DEI HOSPITAL   (Malta)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f UNIVERSITY OF MILAN   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Dose optimization; Infliximab; Loss of response; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; STEROID;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MIDDLE AGED; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; RAPID RESPONSE TEAM; RASH; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VERY ELDERLY; YOUNG ADULT;

DOSE OPTIMIZATION; INFLIXIMAB; LOSS OF RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893691878     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.007     Document Type: Article

References (22)

1. Danese S., Fiocchi C. Ulcerative colitis. New England Journal of Medicine 2011, 365:1713-1725.
2. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
3. Stein R.B., Hanauer S.B. Comparative tolerability of treatments for inflammatory bowel disease. Drug Safety 2000, 23:429-448.
4. Aceituno M., Garcia-Planella E., Heredia C., et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflammatory Bowel Diseases 2008, 14:347-352.
5. Khan K.J., Dubinsky M.C., Ford A.C., et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. The American Journal of Gastroenterology 2011, 106:630-642.
6. Knight D.M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Molecular Immunology 1993, 30:1443-1453.
7. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
8. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
9. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
10. Laharie D., Filippi J., Roblin X., et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Alimentary Pharmacology & Therapeutics 2013, 37:998-1004.
11. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. The American Journal of Gastroenterology 2009, 104:760-767.
12. Allez M., Karmiris K., Louis E., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. Journal of Crohn's and Colitis 2010, 4:355-366.
13. Danese S., Fiorino G., Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Alimentary Pharmacology & Therapeutics 2011, 34:1-10.
14. Hanauer S., Feagan B., Lichtenstein G., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
15. Kopylov U., Mantzaris G.J., Katsanos K.H., et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Alimentary Pharmacology & Therapeutics 2011, 33:349-357.
16. Rostholder E., Ahmed A., Cheifetz A.S., et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2012, 35:562-567.
17. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
18. Satsangi J., Silverberg M.S., Vermeire S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
19. Katz L., Gisbert J.P., Manoogian B., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflammatory Bowel Diseases 2012, 18:2026-2033.
20. Ordas I., Mould D.R., Feagan B.G., et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clinical Pharmacology & Therapeutics 2012, 91:635-646.
21. Taxonera C., Barreiro-de Acosta M., Calvo M.S.C., et al. Short- and long-term outcomes of infliximab dose intensification in patients with ulcerative colitis. Gut 2012, 61:A79.
22. Xie F., Blackhouse G., Assasi N., et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation 2009, 7:20.